All In Biotech

Drug Trial Radar · NCT00241670

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection

Last checked: Nov 20, 2026Latest source record: Apr 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 415 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

415

Actual

Start

Oct 1999

Primary completion

Jul 2004

Sponsor

Lead sponsor
medac GmbHIndustry
Sponsor type
Industry
First posted
Oct 19, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 72 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study "Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.

Conditions

  • Brain Cancer
  • Brain Tumors
  • Cancer of Brain
  • Primary Brain Tumors
  • Brain Tumor, Primary

Interventions

  • 5-aminolevulinic acid (5-ALA)Drug

    1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Percentage of patients with a histologically confirmed malignant glioma (grade III or IV -WHO) without definite residual contrast agent-accumulating tumour in the early post-operative control MRI (within 72 hours of the operation).Time frame: Within 72 hours after surgery
  2. 2. Progression-free survival 6 months after primary surgical treatment of a malignant gli-oma in patients with histologically confirmed malignant glioma (grade III or IV -WHO).Time frame: Within 6 month after surgery

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.